VYNE Therapeutics Completes Enrollment in Phase IIa Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. announced the completion of enrollment in the Phase IIa study of FMX114 for the treatment of mild-to-moderate atopic dermatitis.
[VYNE Therapeutics Inc.]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News